Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | CCND2 | P30279 | 2/20 | 0.44 |
| ▸ | CCND3 | P30281 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035086 | 0.89 | WEE1 (0.40) | CDK4CCND1CCND2CCND3SRC | |
| SCHEMBL15787990 | 0.87 | CDK4 (0.46) | CDK4CCND1CCND2CCND3AXL | |
| SCHEMBL13553613 | 0.78 | RIPK2 (0.41) | CDK4CCND1CCND2CCND3SRC | |
| SCHEMBL15787984 | 0.76 | TYRO3 (0.44) | CDK4CCND1CCND2CCND3AXL | |
| SCHEMBL13553715 | 0.74 | CDK4 (0.41) | CDK4CCND1CCND2CCND3SRC | |
| SCHEMBL14681971 | 0.72 | RIPK2 (0.39) | CDK4CCND1CCND2CCND3AXL | |
| SCHEMBL13553930 | 0.72 | CDK4 (0.40) | CDK4CCND1CCND2CCND3AXL | |
| SCHEMBL15036051 | 0.72 | CDK7 (0.48) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL15787921 | 0.71 | TNK2 (0.35) | CDK4CCND1CCND2CCND3SRC | |
| SCHEMBL13553495 | 0.70 | PKN1 (0.51) | CDK4CCND1CCND2CCND3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | CDK4 98/4885CCND1 2208/4885CCND2 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.